Björn Fischler

Dr. Björn Fischler

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
BFBjörn Fischler
Björn Fischler
TLThierry LAMIREAU
Thierry LAMIREAU

1 September 2009 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
BFBjörn Fischler
Björn Fischler
JSJan F Svensson
Jan F Svensson
ANAntal Nemeth
Antal Nemeth

13 April 2007 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
BFBjörn Fischler
Björn Fischler
KBK. Bodin
K. Bodin
HSH. Stjernman
H. Stjernman
MOM. Olin
M. Olin
MHM. Hansson
M. Hansson
IBI. Björkhem
I. Björkhem

11 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BFBjörn Fischler
Björn Fischler
PCPiotr Czubkowski
Piotr Czubkowski
ADAntal Dezsőfi-Gottl
Antal Dezsőfi-Gottl
ULUlrika Liliemark
Ulrika Liliemark
Piotr SochaPiotr Socha
Piotr Socha
MDMark Davenport
Mark Davenport
Cytomegalovirus (CMV) infection has been suggested to be of importance for the development and outcome of biliary atresia (BA). However, most data are only available from single centre studies. We retrospectively collected data on rates, outcomes, and treatments for ongoing CMV infection at the time of Kasai portoenterostomy (KPE) from four different tertiary centres in Europe. The rate of ongoing CMV infection varied between 10–32% in the four centres. CMV positive patients were significantly older and had higher levels of several liver biochemistries at the time of KPE (p < 0.05 for all comparisons). In the largest centre, CMV infection was more common in non-Caucasians, and CMV infected patients had poorer long-term survival with native liver than CMV negative patients (p = 0.0001). In contrast, survival with native liver in the subgroup of CMV infected patients who had received antiviral treatment was similar to the CMV negative group. We conclude that ongoing CMV infection at the time of KPE occurs in a significant proportion of BA patients and that these patients seem to differ from CMV negative patients regarding age and biochemistry at the time of KPE as well as long-term survival with native liver. The latter difference may be reduced by antiviral treatment, but randomized, controlled trials are needed before such treatment can be recommended routinely.

1 October 2005 in Expert Review of Vaccines
Verified
Journal Article
Closed access
TCThomas H Casswall
Thomas H Casswall
BFBjörn Fischler
Björn Fischler
The development of vaccination is a major achievement in modern medicine. However, children treated with immunosuppression may not at all, or only in part, receive routine immunization due to uncertainty of its risks and effect. There is a substantial lack of pediatric studies concerning the efficacy and safety of vaccination in this patient group. Experience from similar adult groups and children with HIV infection can be used as a model for other disease categories. With increasing knowledge of the immunologic basis of vaccination and how immunosuppressive drugs interfere with the immune system, improved vaccines could be tailored, and adequate, individualized guidelines issued.